nach oben

Inflammation

Erschienen in:

01.02.2015

NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression

verfasst von: Mengran Zhang, Jinqian Zhang, Shunai Liu, Qi Wang, Guoxian Lin, Rongxian Qiu, Min Quan, Jun Cheng

Erschienen in: Inflammation | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Activation of hepatic stellate cell (HSC) is the central event in liver fibrosis. NS5ATP9 is related to many malignant tumors, but little is known about its function in HSC activation. The aim of this study is to investigate the role of NS5ATP9 in HSC activation in vitro. Genes related to liver fibrosis were detected after NS5ATP9 overexpression or silencing with or without transforming growth factor (TGF)-β1 stimulation in the human HSCs by real-time polymerase chain reaction and western blotting. Cell proliferation, migration, and apoptosis were tested, and the mechanisms underlying the effect of NS5ATP9 on HSC activation were studied. We showed that NS5ATP9 suppressed HSC activation and collagen production, with or without TGF-β1 induction. Also, NS5ATP9 inhibited cell proliferation and migration and promoted apoptosis. Furthermore, NS5ATP9 reduced basal and TGF-β1-mediated Smad3/phosphorylated-Smad3 expression. The existence of a physical complex between NS5ATP9 and Smad3 was illustrated. NS5ATP9 suppresses HSC activation, extracellular matrix production, and promotes apoptosis, in part through reducing Smad3/phosphorylated-Smad3 expression.

Nur mit Berechtigung zugänglich

Bataller, R., and D.A. Brenner. 2005. Liver fibrosis. Journal of Clinical Investigation 115: 209–218.CrossRefPubMedCentralPubMed

Mahato, R.I., K. Cheng, and R.V. Guntaka. 2005. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery 2: 3–28.CrossRefPubMed

Friedman, S.L. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655–1669.CrossRefPubMedCentralPubMed

Inagaki, Y., and I. Okazaki. 2007. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 56: 284–292.CrossRefPubMedCentralPubMed

Piek, E., C.H. Heldin, and D.P. Ten. 1999. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB Journal 13: 2105–2124.PubMed

Massague, J. 2000. How cells read TGF-beta signals. Nature Reviews Molecular Cell Biology 1: 169–178.CrossRefPubMed

Yu, P., B. Huang, M. Shen, et al. 2001. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 20: 484–489.CrossRefPubMed

Shi, L., S.L. Zhang, K. Li, et al. 2008. NS5ATP9, a gene up-regulated by HCV NS5A protein. Cancer Letters 259: 192–197.CrossRefPubMed

Kato, T., Y. Daigo, M. Aragaki, K. Ishikawa, M. Sato, and M. Kaji. 2012. Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer 75: 110–118.CrossRefPubMed

10.

Liu, L., X. Chen, S. Xie, C. Zhang, Z. Qiu, and F. Zhu. 2012. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology 56: 1760–1769.CrossRefPubMed

11.

Li, K., Q. Ma, L. Shi, et al. 2008. NS5ATP9 gene regulated by NF-kappaB signal pathway. Archives of Biochemistry and Biophysics 479: 15–9.CrossRefPubMed

12.

Mizutani, K., M. Onda, S. Asaka, et al. 2005. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. Cancer 103: 1785–1790.CrossRefPubMed

13.

Yuan, R.H., Y.M. Jeng, H.W. Pan, et al. 2007. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clinical Cancer Research 13: 5368–5376.CrossRefPubMed

14.

Emanuele, M.J., A. Ciccia, A.E. Elia, and S.J. Elledge. 2011. Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proceedings of the National Academy of Sciences of the United States of America 108: 9845–9850.CrossRefPubMedCentralPubMed

15.

Turchi, L., M. Fareh, E. Aberdam, et al. 2009. ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death and Differentiation 16: 728–737.CrossRefPubMed

16.

Quan M, Liu S, Li G, et al. 2013. A functional role for NS5ATP9 in the induction of HCV NS5A-mediated autophagy. J Viral Hepat, accepted.

17.

Xu, L., A.Y. Hui, E. Albanis, et al. 2005. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142–151.CrossRefPubMedCentralPubMed

18.

Chen, Y.L., J. Lv, X.L. Ye, et al. 2011. Sorafenib inhibits transforming growth factor beta1-mediated epithelial–mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 53: 1708–1718.CrossRefPubMed

19.

Xiao, X., Y. Gang, Y. Gu, et al. 2012. Osteopontin contributes to TGF-beta1 mediated hepatic stellate cell activation. Digestive Diseases and Sciences 57: 2883–2891.CrossRefPubMed

20.

Shimada, H., N.R. Staten, and L.E. Rajagopalan. 2011. TGF-beta1 mediated activation of Rho kinase induces TGF-beta2 and endothelin-1 expression in human hepatic stellate cells. Journal of Hepatology 54: 521–528.CrossRefPubMed

21.

Lim, J.Y., M.A. Oh, W.H. Kim, H.Y. Sohn, and S.I. Park. 2012. AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. Journal of Cellular Physiology 227: 1081–1089.CrossRefPubMed

22.

Krizhanovsky, V., M. Yon, R.A. Dickins, et al. 2008. Senescence of activated stellate cells limits liver fibrosis. Cell 134: 657–667.CrossRefPubMedCentralPubMed

23.

Shi, Y., and J. Massague. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700.CrossRefPubMed

24.

Massague, J., and Y.G. Chen. 2000. Controlling TGF-beta signaling. Genes and Development 14: 627–644.PubMed

25.

Jiao, J., S.L. Friedman, and C. Aloman. 2009. Hepatic fibrosis. Current Opinion in Gastroenterology 25: 223–229.CrossRefPubMedCentralPubMed

26.

Lotersztajn, S., B. Julien, F. Teixeira-Clerc, P. Grenard, and A. Mallat. 2005. Hepatic fibrosis: molecular mechanisms and drug targets. Annual Review of Pharmacology and Toxicology 45: 605–628.CrossRefPubMed

27.

Friedman, S.L. 2008. Hepatic fibrosis—overview. Toxicology 254: 120–129.CrossRefPubMed

28.

Jain, M., L. Zhang, E.E. Patterson, and E. Kebebew. 2011. KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS ONE 6: e26866.CrossRefPubMedCentralPubMed

29.

Hosokawa, M., A. Takehara, K. Matsuda, et al. 2007. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Research 67: 2568–2576.CrossRefPubMed

30.

Guo, M., J. Li, D. Wan, and J. Gu. 2006. KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. BMC Cancer 6: 109.CrossRefPubMedCentralPubMed

31.

Wang, Q., Y. Wang, Y. Li, X. Gao, S. Liu, and J. Cheng. 2013. NS5ATP9 contributes to inhibition of cell proliferation by hepatitis C virus (HCV) nonstructural protein 5A (NS5A) via MEK/extracellular signal regulated kinase (ERK) pathway. International Journal of Molecular Sciences 14: 10539–10551.CrossRefPubMedCentralPubMed

32.

Simpson, F., K.L. Lammerts van Bueren, N. Butterfield, et al. 2006. The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Experimental Cell Research 312: 73–85.CrossRefPubMed

Titel: NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression
verfasst von: Mengran Zhang
Jinqian Zhang
Shunai Liu
Qi Wang
Guoxian Lin
Rongxian Qiu
Min Quan
Jun Cheng
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-014-0031-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Relevance of the Myeloid Differentiation Factor 88 (MyD88) on RANKL, OPG, and Nod Expressions Induced by TLR and IL-1R Signaling in Bone Marrow Stromal Cells

Lipoxin A4 Suppresses Lipopolysaccharide-Induced Hela Cell Proliferation and Migration via NF-κB Pathway

Noninvasive Allograft Imaging of Acute Rejection: Evaluation of 131I-anti-CXCL10 mAb

Differential Induction of Inflammatory Cytokines and Reactive Oxygen Species in Murine Peritoneal Macrophages and Resident Fresh Bone Marrow Cells by Acute Staphylococcus aureus Infection: Contribution of Toll-Like Receptor 2 (TLR2)

Intra-articular (IA) Ropivacaine Microparticle Suspensions Reduce Pain, Inflammation, Cytokine, and Substance P Levels Significantly More than Oral or IA Celecoxib in a Rat Model of Arthritis